AbbVie Plans Faster U.S. Facility Construction Due to New Tariff Policies
In response to the U.S. government’s 100% tariff on branded drugs imposed last October, AbbVie announced plans to expand its U.S. manufacturing operations. The tariffs only affect companies that had not yet begun construction on domestic facilities, giving AbbVie an incentive to accelerate its plans.
New North Chicago Facility
AbbVie confirmed that construction of its new North Chicago, Illinois, facility will start in spring 2026. Both new plants are expected to be fully operational by 2029, incorporating cutting-edge manufacturing technologies and artificial intelligence to support the production of future pipeline medicines.
Advanced Pharmaceutical Production
The company highlighted that the production of active pharmaceutical ingredients (APIs) – the critical chemical components of drugs – is among the most complex steps in manufacturing. The new facilities will enhance AbbVie’s ability to manage these intricate processes more efficiently.
Job Creation
The North Chicago expansion is expected to create 300 new jobs, including engineers, scientists, manufacturing operators, and lab technicians. This is part of AbbVie’s broader commitment to growing its domestic workforce and capabilities.
Long-Term U.S. Investment
In January, AbbVie pledged $100 billion over the next decade for U.S.-based research and development. This includes a previous $195 million expansion at the same North Chicago site to increase API production for immunology, oncology, and neuroscience therapies.
Nationwide Manufacturing Growth
AbbVie currently operates 11 U.S. manufacturing sites and is exploring additional projects with multiple states. The company expects to announce further investments in 2026 as part of its strategy to strengthen domestic pharmaceutical production.
Responding to Trade Pressures
The investment aligns with AbbVie’s effort to scale up U.S. manufacturing amid heavy tariffs on pharmaceutical imports under the Trump administration. The expansion aims to ensure the company maintains robust domestic production capacity and inventory while navigating trade restrictions.
